ArticleAnnals of translational medicine2022
The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan-effectiveness, pitfalls and promises.
Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- T-Cell Engagers in Lung Cancer: A Comprehensive Literature Review from Tarlatamab Approval to Next-Generation Strategies.Cancers · 2026Review
- Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting.EJNMMI research · 2026Review
- Integrated electrophysiological and payload-release assessment of neuronal responses to antibody-drug conjugates in human iPSC-derived sensory neurons: implications forFrontiers in toxicology · 2026Article
- Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences.Cancer chemotherapy and pharmacology · 2025Review
- Article
- Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy.International journal of molecular sciences · 2025Article
- Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report.Therapeutic advances in medical oncology · 2025Article
- A Review of Current and Future Antibody Drug Conjugates in Breast Cancer.Current treatment options in oncology · 2024Review
- Antibody-Drug Conjugates in the Treatment of Genitourinary Cancers: An Updated Review of Data.Current oncology (Toronto, Ont.) · 2024Review
- Pioneering the Way: The Revolutionary Potential of Antibody-Drug Conjugates in NSCLC.Current treatment options in oncology · 2024Review
- Trop2-targeted therapies in solid tumors: advances and future directions.Theranostics · 2024Review
- Antibody Polymer Conjugates (APCs) for Active Targeted Therapeutic Delivery.Biomacromolecules · 2023Article
- Article
- Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies.International journal of molecular sciences · 2023Review
- Targeted Drug Delivery Using a Plug-to-Direct Antibody-Nanogel Conjugate.Biomacromolecules · 2023Article
- Targeting Trop2 in solid tumors: a look into structures and novel epitopes.Frontiers in immunology · 2023Review
- A non-mutatedFrontiers in oncology · 2023Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.